Analyst Ratings For PRQR – ProQR Therapeutics (NASDAQ:PRQR)
Today, Chardan Capital initiated coverage on PRQR – ProQR Therapeutics (NASDAQ:PRQR) with a Buy with a price target of $4.50.
Some recent analyst ratings include
- 4/5/2018-Chardan Capital initiated coverage with a Buy rating.
- 9/26/2017-Leerink Swann Reiterated Rating of Outperform.
- 9/26/2017-HC Wainwright Reiterated Rating of Buy.
- 9/28/2016-Janney Montgomery Scott initiated coverage with a Neutral rating.
Recent Trading Activity for PRQR – ProQR Therapeutics (NASDAQ:PRQR)
Shares of PRQR – ProQR Therapeutics closed the previous trading session at 3.00 up +0.05 1.69% with 34445 shares trading hands.